Screening of infants and mortality due to neuroblastoma.

BACKGROUND Neuroblastoma, the most common extracranial solid tumor that occurs in early childhood, can be identified in the preclinical stages by the detection of catecholamines in the urine. However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease. METHODS Through their parents, we offered screening for neuroblastoma at three weeks and six months of age to all 476,654 children born in the province of Quebec, Canada, during a five-year period (May 1, 1989, through April 30, 1994). The participation rate was 92 percent. The rate of death due to neuroblastoma was determined and compared with the rates in several unscreened control populations born during the same period. RESULTS Among children younger than eight years of age in the Quebec cohort, there were 22 deaths due to neuroblastoma; the cumulative (+/-SE) mortality rate due to neuroblastoma was 4.78+/-1.14 per 100,000 children over a period of nine years. The standardized incidence ratios for death due to neuroblastoma for the Quebec cohort were 1.11 (95 percent confidence interval, 0.64 to 1.92) as compared with a control group in Ontario, Canada; 0.90 (95 percent confidence interval, 0.48 to 1.70) as compared with a control group in Minnesota; 1.40 (95 percent confidence interval, 0.81 to 2.41) as compared with a control group in Florida; and 0.96 (95 percent confidence interval, 0.56 to 1.66) as compared with a control group in the Greater Delaware Valley. The standardized mortality ratio for the Quebec cohort as compared with the rest of Canada was 1.39 (95 percent confidence interval, 0.85 to 2.30); the odds ratio for the comparison with a cohort born in Quebec before the screening program began was 0.98 (95 percent confidence interval, 0.54 to 1.77). CONCLUSIONS Screening infants for neuroblastoma does not appear to reduce mortality due to this disease.

[1]  M. Tuchman,et al.  A population-based study of the usefulness of screening for neuroblastoma , 1996, The Lancet.

[2]  M. Tuchman,et al.  Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. , 1992, Pediatrics.

[3]  R. Castleberry,et al.  Biology and treatment of neuroblastoma. , 1997, Pediatric clinics of North America.

[4]  M. Tuchman,et al.  Biological aspects of neuroblastomas identified by mass screening in Quebec. , 2001, Medical and pediatric oncology.

[5]  L. Foxhall,et al.  Neuroblastoma screening in the united states , 1998, Cancer.

[6]  W. Woods,et al.  Randomized controlled trials in population-based intervention studies are not always feasible. , 1999, Medical and pediatric oncology.

[7]  W. Woods,et al.  Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers , 1997, Cancer Causes & Control.

[8]  M. Nishi,et al.  Effects of the mass screening of neuroblastoma in sapporo city , 1987, Cancer.

[9]  W. Woods.  Screening for neuroblastoma in infants: more questions than answers , 1992 .

[10]  R. Hanada,et al.  Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[12]  J. Shuster,et al.  A population-based study of neuroblastoma incidence, survival, and mortality in North America. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Bessho,et al.  Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. , 1991, The Journal of pediatrics.

[14]  Y. Kaneko,et al.  Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[16]  A. Evans,et al.  Incidence of childhood cancer: experience of a decade in a population-based registry. , 1983, Journal of the National Cancer Institute.

[17]  F. Berthold,et al.  Neuroblastoma screening at one year of age. , 2002, The New England journal of medicine.

[18]  P. Prorok,et al.  Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening , 1991, The Lancet.

[19]  M. Tuchman,et al.  Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. , 1990, Pediatrics.

[20]  T. Sawada,et al.  MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.

[21]  F. Bessho,et al.  Effects of mass screening on age‐specific incidence of neuroblastoma , 1996, International journal of cancer.

[22]  B. Pollock,et al.  Childhood cancer in the united states: A geographical analysis of cases from the Pediatric Cooperative Clinical Trials Groups , 1996, Cancer.

[23]  A. Nakagawara,et al.  Molecular Basis of Clinical Heterogeneity in Neuroblastoma , 1992, The American journal of pediatric hematology/oncology.

[24]  R. Hanada,et al.  Spontaneous regression of localized neuroblastoma detected by mass screening. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Okamura,et al.  Mass screening for neuroblastoma at 6 months of age: difficult to justify. , 1998, Journal of pediatric surgery.

[26]  L. I. Gardner,et al.  Studies of catecholamine excretion by children with neural tumors. , 1962, The Journal of clinical endocrinology and metabolism.